Toggle navigation
About
Abstract
Editorial Board
Subscription & Newsletter
Contact
Issues
This issue
22-3
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
22-3
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #53152
advertisement
Dunaief JL
7
Showing records 1 to 7 |
Display all abstracts from
Dunaief JL
95905
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Sterling J
British Journal of Ophthalmology
2023; 107: 215-220
96310
Myeloid cells in retinal and brain degeneration
Guo M; Schwartz TD
FEBS Journal
2022; 289: 2337-2361
95905
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Hua P
British Journal of Ophthalmology
2023; 107: 215-220
96310
Myeloid cells in retinal and brain degeneration
Dunaief JL
FEBS Journal
2022; 289: 2337-2361
95905
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Dunaief JL
British Journal of Ophthalmology
2023; 107: 215-220
96310
Myeloid cells in retinal and brain degeneration
Cui QN
FEBS Journal
2022; 289: 2337-2361
95905
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Cui QN; Vanderbeek BL
British Journal of Ophthalmology
2023; 107: 215-220
Issue
22-3
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept